Resultado de búsqueda
We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer, and infectious diseases and other serious diseases. As immune engineers we have a deep understanding of the underlying mechanisms that enable the immune system to effectively recognize both external threats like infectious diseases and internal threats like cancer.
- Imprint
Imprint - BioNTech
- Newsroom
Videos, photos, press releases or data sheets Learn more...
- Data Privacy Statement
Welcome to our privacy page. At BioNTech, privacy means fair...
- Terms of Use
BioNTech SE has compiled the content of this website with...
- Connect
At BioNTech, we believe that acting ethically and...
- About
BioNTech’s portfolio contains more than 25 product...
- Research & Innovation
Research & Innovation - BioNTech
- mRNA Platforms
The architecture of our FixVac platform. Our FixVac (Fixed...
- Imprint
7 de oct. de 2019 · This logo image consists only of simple geometric shapes or text. It does not meet the threshold of originality needed for copyright protection, and is therefore in the public domain. Although it is free of copyright restrictions, this image may still be subject to other restrictions.
23 de nov. de 2023 · File. : BioNTech logo.svg. Size of this PNG preview of this SVG file: 800 × 93 pixels. Other resolutions: 320 × 37 pixels | 640 × 74 pixels | 1,024 × 119 pixels | 1,280 × 149 pixels | 2,560 × 298 pixels. Original file (SVG file, nominally 1,024 × 119 pixels, file size: 4 KB)
BioNTech SE (/ b iː ˈ ɒ n t ɛ k / bee-ON-tek; or / b aɪ ˈ ɒ n t ɛ k / bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
6 de ene. de 2021 · Actualizado 08/01/2021. El nuevo logo de Pfizer se actualiza para presentasarse como una nueva compañia que se dedica a la investigación científica y tecnológica.
BioNTech recibió entonces 375 millones, mientras que su competidora CureVac obtuvo 252 millones. [26] También en 2020, la Comisión Europea cerró un contrato con ambas farmacéuticas para hacerse con 300 millones de dosis, de las que Alemania recibirá un porcentaje.
File. : BioNTech Logo neu.svg. Size of this PNG preview of this SVG file: 512 × 56 pixels. Other resolutions: 320 × 35 pixels | 640 × 70 pixels | 1,024 × 112 pixels | 1,280 × 140 pixels | 2,560 × 280 pixels. Original file (SVG file, nominally 512 × 56 pixels, file size: 2 KB)
